GHK-Cu vs Palmitoyl Tripeptide-5

Overview

GHK-Cu is primarily a pain management peptide, while Palmitoyl Tripeptide-5 is used for cosmetic & skin.

This page compares GHK-Cu and Palmitoyl Tripeptide-5 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.

Side-by-side comparison

Key differences

Primary use. GHK-Cu is categorised under Pain Management, while Palmitoyl Tripeptide-5 falls under Cosmetic & Skin. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.

Regulatory status. GHK-Cu: not FDA-approved; compounding permitted with a prescription as of April 2026. Palmitoyl Tripeptide-5: not FDA-approved; treated as a research compound.

Dosing. GHK-Cu is typically dosed at 1-3 mg (daily). Palmitoyl Tripeptide-5 is typically dosed at Topical formulation (daily).

Can you stack them?

Some protocols combine peptides, but stacking GHK-Cu and Palmitoyl Tripeptide-5 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.

Frequently asked questions

What is the difference between GHK-Cu and Palmitoyl Tripeptide-5?

GHK-Cu is primarily a pain management peptide, while Palmitoyl Tripeptide-5 is used for cosmetic & skin. GHK-Cu is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Palmitoyl Tripeptide-5 is not FDA-approved; generally classified as a research compound.

What is GHK-Cu used for?

Anti-inflammatory tissue repair.

What is Palmitoyl Tripeptide-5 used for?

Collagen booster.

Can you take GHK-Cu and Palmitoyl Tripeptide-5 together?

Some users combine peptides within a single protocol, but stacking GHK-Cu and Palmitoyl Tripeptide-5 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.

Is GHK-Cu or Palmitoyl Tripeptide-5 FDA-approved?

GHK-Cu is not FDA-approved; compounding permitted with a prescription (as of April 2026). Palmitoyl Tripeptide-5 is not FDA-approved; generally classified as a research compound.